menu

Improving Pump Function in Heart Failure with Reduced Ejection Fraction

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Improving Pump Function in Heart Failure with Reduced Ejection Fraction

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction (HFrEF) is the initial decrease in systolic function.  The purpose of inotropic interventions in HF is to increase the muscular contractile force of the myocardium.  Current intravenous inotropes and previously investigated oral positive inotropic drugs exert their effect by modulating calcium signaling in the myocardium.  Results from clinical trials with these agents have indicated poor long-term outcomes and signals of increased mortality. Emerging pharmacological agents that improve contraction by novel mechanisms of action may be able to improve clinical outcomes for patients with chronic HFrEF.  In this educational initiative, a panel of HF experts will 1) discuss the concept of inotropy, describe previous attempts to improve clinical outcomes with inotropes, and summarize their current use 2) explain new calcium-independent approaches to improve myocardial contractility, and 3) interpret recently published evidence and potential implications for clinical practice.

  • Disclosure of Conflicts of Interest

    It is the policy of Voxmedia to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose any significant financial, other interest or relationship (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only then may faculty receive approval to participate, and are expected to contribute evidence-based material and information. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis etc. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will make the required disclosure to the audience.  It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. In addition, presenters must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

    Host:
    G. Michael Felker, MD, MHS
    Professor of Medicine, Division of Cardiology
    Vice-Chief of Cardiology for Clinical Research
    Therapeutic Area Lead, Cardiovascular Research,
    Duke Clinical Research Institute
    Durham, NC
    Grant Support: American Heart Association, Amgen, Bayer, NHLBI,  Novartis, Merck, Myokardia
    Consultant: Abbott, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Cardionomic, Cytokinetics, Innolife, Medtronic, Novartis, Reprieve
    Endpoint Adjudication Committees/DSMBs: Amgen, EBR Systems, LifaNova, Medtronic, Merck, Rocket Pharma, Siemens, V-Wave
    Journals: Associate Editor, JACC: Heart Failure; Guest Editor, JACC; Guest Editor, Circulation

    Faculty:
    Nancy K. Sweitzer, MD, PhD
    Professor of Medicine
    Chief of Cardiology
    Director, Sarver Heart Center
    University of Arizona
    Tucson, AZ
    Grants/Research Support: Merck, NIH 
    Consultant: Myokardia
    Honorarium: Medscape
    Other Financial or Material Support:  American Heart Association

    John R. Teerlink, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    Director of Heart Failure
    San Francisco Veterans Affairs Medical Center
    San Francisco, CA
    ConsultantAbbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis, Windtree Therapeutics
    Contracted Research: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cytokinetics, Medtronic, Novartis, Windtree Therapeutics

    Reviewer/Content Planner:
    Voxmedia
    John F. Kocsis, PhD
    President
    Springfield, NJ
    Dr. Kocsis indicated he has nothing to disclose.

  • Target Audience

    This educational activity is intended for cardiovascular clinicians.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Explain the concept of inotropy
    2. Identify prior attempts to improve clinical outcomes with inotropes
    3. Recognize current appropriate use of inotropic therapy and identify settings where it is not recommended
    4. Describe the mechanism of action, and effects on cardiac function of omecamtiv mecarbil, an investigational myotrope 
    5. Discuss the effects of selective cardiac myosin activation on cardiovascular outcomes in chronic HF patients with reduced EF
  • Accreditation and Credit Designation Statements

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Voxmedia LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

  • Provider(s)/Educational Partner(s)

    Provided by ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational donation provided by Amgen.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction (HFrEF) is the initial decrease in systolic function.  The purpose of inotropic interventions in HF is to increase the muscular contractile force of the myocardium.  Current intravenous inotropes and previously investigated oral positive inotropic drugs exert their effect by modulating calcium signaling in the myocardium.  Results from clinical trials with these agents have indicated poor long-term outcomes and signals of increased mortality. Emerging pharmacological agents that improve contraction by novel mechanisms of action may be able to improve clinical outcomes for patients with chronic HFrEF.  In this educational initiative, a panel of HF experts will 1) discuss the concept of inotropy, describe previous attempts to improve clinical outcomes with inotropes, and summarize their current use 2) explain new calcium-independent approaches to improve myocardial contractility, and 3) interpret recently published evidence and potential implications for clinical practice.

  • Disclosure of Conflicts of Interest

    It is the policy of Voxmedia to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose any significant financial, other interest or relationship (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only then may faculty receive approval to participate, and are expected to contribute evidence-based material and information. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis etc. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will make the required disclosure to the audience.  It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. In addition, presenters must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

    Host:
    G. Michael Felker, MD, MHS
    Professor of Medicine, Division of Cardiology
    Vice-Chief of Cardiology for Clinical Research
    Therapeutic Area Lead, Cardiovascular Research,
    Duke Clinical Research Institute
    Durham, NC
    Grant Support: American Heart Association, Amgen, Bayer, NHLBI,  Novartis, Merck, Myokardia
    Consultant: Abbott, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Cardionomic, Cytokinetics, Innolife, Medtronic, Novartis, Reprieve
    Endpoint Adjudication Committees/DSMBs: Amgen, EBR Systems, LifaNova, Medtronic, Merck, Rocket Pharma, Siemens, V-Wave
    Journals: Associate Editor, JACC: Heart Failure; Guest Editor, JACC; Guest Editor, Circulation

    Faculty:
    Nancy K. Sweitzer, MD, PhD
    Professor of Medicine
    Chief of Cardiology
    Director, Sarver Heart Center
    University of Arizona
    Tucson, AZ
    Grants/Research Support: Merck, NIH 
    Consultant: Myokardia
    Honorarium: Medscape
    Other Financial or Material Support:  American Heart Association

    John R. Teerlink, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    Director of Heart Failure
    San Francisco Veterans Affairs Medical Center
    San Francisco, CA
    ConsultantAbbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis, Windtree Therapeutics
    Contracted Research: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cytokinetics, Medtronic, Novartis, Windtree Therapeutics

    Reviewer/Content Planner:
    Voxmedia
    John F. Kocsis, PhD
    President
    Springfield, NJ
    Dr. Kocsis indicated he has nothing to disclose.

  • Target Audience

    This educational activity is intended for cardiovascular clinicians.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Explain the concept of inotropy
    2. Identify prior attempts to improve clinical outcomes with inotropes
    3. Recognize current appropriate use of inotropic therapy and identify settings where it is not recommended
    4. Describe the mechanism of action, and effects on cardiac function of omecamtiv mecarbil, an investigational myotrope 
    5. Discuss the effects of selective cardiac myosin activation on cardiovascular outcomes in chronic HF patients with reduced EF
  • Accreditation and Credit Designation Statements

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Voxmedia LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

  • Provider(s)/Educational Partner(s)

    Provided by ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational donation provided by Amgen.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 Nov 2021
Webpack App